About us

Our Company

Inbiomotion is a Science driven company founded in 2010 based on de novo discovery of MAF gene as effective biomarker for bone metastasis. We are a spin-out of IRB Barcelona and ICREA research labs, VC-backed, founded by scientists to combine clinical and technology innovation for the benefit of patients in precision medicine.

Mission

Launch a personalized adjuvant therapy and improve breast cancer patients' risk of relapse and overall survival.

Vision

To be a global leader in developing and applying biomarker tools that prevent cancer recurrence. We identify promising scientific laboratory results and making them available for clinical use in benefit of cancer patients.

|Alt Imatge Our Company|

Board of directors and management

Scientific and clinical advisory board

  • Prof Rob E. Coleman · MD, MBBS, FRCP, FRCPE · Chairman

    Expertise: bone oncology, breast cancer, clinical cancer research, clinical trials

    Dr. Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield, UK. Dr. Coleman has been instrumental in developing clinical cancer research and in establishing an internationally respected bone oncology research team in Sheffield. Dr. Coleman has held many leadership roles within the university and the UK National Institute for Health Research (NIHR) Cancer Research Network. Dr. Coleman has developed a highly successful cancer clinical trials facility, which has both led and participated in a broad range of clinical trials-ranging from early phase drug development studies to large phase III randomised trials. In 2020, Dr. Colemen and co-workers published the ESMO Clinical Practice Guidelines for bone health in cancer.

  • Prof Dan F. Hayes · MD

    Expertise: breast cancer, clinical biomarker validation, clinical trials, personalized medicine

    Dr. Hayes is the Stuart B. Padnos Professor of Breast Cancer Research.at the University of Michigan Rogel Cancer Center. He chairs, or has chaired, several national and international scientific committees, including the Breast Cancer Translational Medicine subcommittee of SWOG, in which he mentored young investigators from other centers. He was the inaugural recipient of the American Society of Clinical Oncology (ASCO) Gianni Bonadonna Breast Cancer Award (2007), given for achievement in translational research and mentoring, and has held many leadership roles in ASCO, including a three-year Presidential term of office (2015-2018). He is a Fellow of ASCO, a Fellow of the American College of Physicians, a Komen Scholar, and a member of the Association of American Physicians and the American Clinical and Climatologic Association.

  • Prof Andrew Tutt · MD

    Expertise: breast cancer, TNBC, clinical trials, translational research, clinical oncology

    Professor Tutt is Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR and Guy's Hospital King's College London. He is a Clinician Scientist with the Laboratory and Clinical Trials programme, and a Consultant Clinical Oncologist looking after women with breast cancer. He is also a member of the St Gallen early breast cancer international guidelines consensus panel.

  • Prof Joan Albanell · MD

    Expertise: breast cancer, clinical trials, medical oncology

    Professor Albanell is the head of the medical oncology department at Hospital del Mar in Barcelona. He is a founding member of GEICAM (Spanish Group of Breast Cancer Research), coordinator of the group transGEICAM and member of the board of directors of SEOM (Spanish Society of Medical Oncology).

Investors